PDF Downloads
Time marches on yet valuable lessons learned stay current.
Complexity be damned: the need to better use biology to achieve more impactful cell therapies
Biological complexity is both a benefit and a bane of cell therapy. An astute partnership with nature is required to achieve a reliable clinical outcome from cell therapy. To accomplish it, we must dig deep enough to acquire knowledge crucial to translation, while maintaining a perspective that will prevent misdirection. Not every bit of information will be of equal importance, yet we can’t skip over or miss what could be pivotal. Dealing with the biological complexity surrounding cell therapy may seem like a risky balancing act. However, luck favors the prepared, and there are practices we can employ to reduce translational risk and form a clinically impactful collaboration between science and nature.Cell & Gene Therapy Insights February 3, 2020; 6(1), 41–46.
Eight Ways to Evaluate Emerging Clinical-Stage Biotechnology
Clinical trials are generally viewed as a sign that a company has progressed to the next stage and investors usually perceive it as very important validation of a technology and team. Can one really tell what entry into clinical trials are harbingers of a costly misstep, or a true step forward for the company and its investors? In many cases, yes!How to Make the Transition From Academic Research to Biotechnology: Twelve Traits of Outstanding Industrial Scientists
Whether you are at the end of your postdoctoral fellowship contemplating your next move, a distinguished professor being considered for that big position, or a new founder of a biotech start-up, a savvy appreciation of how science and research differsin industry can make you a more valuable player, ease the transition and help you achieve a successful and personally rewarding career in industry.Positioned for Success: Building a Biological Product Using a High-Value Preclinical Plan
The ultimate medical and commercial success of biological products is dependent on both an efficient discovery and development strategy prior to entry into the clinic. The high-value preclinical plan is one that lays the foundation for success, absence of a well-designed preclinical plan can create weaknesses in product design, lead to poor choice of clinical target and protocol design or failure to pass regulatory muster. It also leaves a door open for the competition.Reducing Risk in Bioscience Development: Closing the Information to Knowledge Gap
Top biotechnology R&D executives maintain the vision of the company and often represent the most knowledgeable and experienced members of the team. In most biotechnology companies, the future success of the company is often riding on their decisions. Their decisions must be informed, astute and insightful. Productive insight is the definition for breakthrough and a company looks to its scientific leadership to provide that insight, set a productive pipeline strategy, make its products, and keep it competitive.Presentation: Drucker's Management Essentials for Today's Life Science
Top biotechnology R&D executives maintain the vision of the company and often represent the most knowledgeable and experienced members of the team. In most biotechnology companies, the future success of the company is often riding on their decisions. Their decisions must be informed, astute and insightful. Productive insight is the definition for breakthrough and a company looks to its scientific leadership to provide that insight, set a productive pipeline strategy, make its products, and keep it competitive.Presentation: Translating Complex Biology:Basic Principles That Fuel Successful R&D
While companies large and small aspire to highly productive R&D, these days, too few experience ultimate success from their R&D efforts. Is it mostly luck or are there key elements that can propel your product to the clinic and ultimately to the market?E-book from The Parenteau BioConsultants & BioRankings Alliance:
Immunotherapy Demystified: Investing in High Risk, High Reward Opportunities in Cancer Therapeutics (2009)
A Parenteau BioConsultants & BioRankings Alliance Briefing:
FDA to Re-evaluate Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease (2010)